Conor gets six-month study boost for drug-eluting CoStar stent; firm forms multi-drug pact with novartis
This article was originally published in Clinica
Executive Summary
Six-month follow-up results from a pivotal European trial of Conor Medsystems' cobalt chromium paclitaxel-eluting stent, CoStar, have shown consistently low restenosis and complication rates for the product across an array of patients. So reported the Menlo Park, California company, which also recently signed a deal to evaluate the delivery of different drugs from its stents.